KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Q4 2025 value amounting to $134.7 million.

  • Alnylam Pharmaceuticals' Shares Outstanding (Diluted Average) rose 550.96% to $134.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $134.7 million, marking a year-over-year increase of 550.96%. This contributed to the annual value of $134.7 million for FY2025, which is 550.96% up from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' Shares Outstanding (Diluted Average) is $134.7 million, which was up 550.96% from $137.3 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Shares Outstanding (Diluted Average) high stood at $137.3 million for Q3 2025, and its period low was $117.1 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $124.8 million (2023), whereas its average is $125.2 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Shares Outstanding (Diluted Average) surged by 750.7% in 2023 and then plummeted by 209.16% in 2024.
  • Over the past 5 years, Alnylam Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $118.5 million in 2021, then grew by 2.73% to $121.7 million in 2022, then grew by 2.64% to $124.9 million in 2023, then increased by 2.2% to $127.7 million in 2024, then grew by 5.51% to $134.7 million in 2025.
  • Its last three reported values are $134.7 million in Q4 2025, $137.3 million for Q3 2025, and $130.6 million during Q2 2025.